Enanta Pharmaceuticals (ENTA) Receivables (2012 - 2026)

Enanta Pharmaceuticals' Receivables history runs 15 years deep, the most recent figure standing at $7.8 million for Q1 2026.

• Quarterly Receivables rose 14.97% year-over-year to $7.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.8 million (up 14.97% YoY) and the FY2025 annual result came in at $6.9 million, up 3.55% from the prior year.
• Receivables was $7.8 million for Q1 2026 at Enanta Pharmaceuticals, down from $8.5 million in the prior quarter.
• Across five years, Receivables topped out at $22.6 million in Q4 2022 and bottomed at $6.6 million in Q3 2024.
• A 5-year average of $12.0 million and a median of $8.3 million in 2025 frame the typical range for Receivables.
• Annual changes were most pronounced in 2023 — Receivables sank 63.81% — and 2026, when it grew 14.97%.
• Enanta Pharmaceuticals' Receivables stood at $22.6 million in 2022, then sank by 63.81% to $8.2 million in 2023, then fell by 5.57% to $7.7 million in 2024, then advanced by 10.04% to $8.5 million in 2025, then slipped by 8.05% to $7.8 million in 2026.
• Business Quant data shows ENTA's Receivables at $7.8 million in Q1 2026, $8.5 million in Q4 2025, and $6.9 million in Q3 2025.